New drug combo aims to wipe out lingering leukemia cells
NCT ID NCT04216563
Summary
This study tested whether adding a new drug called ABL001 to standard CML medications could help patients achieve a deeper remission. It was for patients who still had very low levels of detectable leukemia despite being on long-term treatment. The goal was to see if the two-drug combination could clear these remaining cells better than the standard drug alone, potentially allowing patients to safely stop therapy in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME NEGATIVE, BCR-ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.